Stock Analysis
Top 3 Swedish Growth Stocks With High Insider Ownership
Reviewed by Simply Wall St
In the midst of global economic uncertainties and fluctuating market conditions, Sweden's stock market has shown resilience, particularly in its growth sectors. As investors seek stability and potential upside, companies with high insider ownership often stand out due to their alignment of interests with shareholders. Identifying stocks that combine robust growth prospects with significant insider ownership can be a prudent strategy. This article highlights three Swedish growth companies where insiders have substantial stakes, suggesting confidence in their long-term potential.
Top 10 Growth Companies With High Insider Ownership In Sweden
Name | Insider Ownership | Earnings Growth |
CTT Systems (OM:CTT) | 16.9% | 24.8% |
Biovica International (OM:BIOVIC B) | 18.7% | 73.8% |
Magle Chemoswed Holding (OM:MAGLE) | 14.9% | 72.2% |
Yubico (OM:YUBICO) | 37.5% | 43.8% |
InCoax Networks (OM:INCOAX) | 18.1% | 104.9% |
BioArctic (OM:BIOA B) | 34% | 104.2% |
KebNi (OM:KEBNI B) | 37.8% | 90.4% |
Calliditas Therapeutics (OM:CALTX) | 11.6% | 52.9% |
SaveLend Group (OM:YIELD) | 23.3% | 103.4% |
edyoutec (NGM:EDYOU) | 13.4% | 63.1% |
Underneath we present a selection of stocks filtered out by our screen.
BioArctic (OM:BIOA B)
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (publ) develops biological drugs for central nervous system disorders in Sweden and has a market cap of SEK13.87 billion.
Operations: BioArctic's revenue from biotechnology amounts to SEK252.21 million.
Insider Ownership: 34%
Earnings Growth Forecast: 104.2% p.a.
BioArctic, a growth company with high insider ownership in Sweden, has experienced volatile share prices but remains significantly undervalued. The company's revenue is forecast to grow at 39.1% per year, outpacing the market's 1.1%. Recent approvals of Leqembi for Alzheimer's treatment in Hong Kong and South Korea bolster its growth prospects. Despite a challenging first quarter with SEK 57.56 million net loss, analysts expect substantial price appreciation and profitability within three years.
- Get an in-depth perspective on BioArctic's performance by reading our analyst estimates report here.
- Insights from our recent valuation report point to the potential undervaluation of BioArctic shares in the market.
CTT Systems (OM:CTT)
Simply Wall St Growth Rating: ★★★★★★
Overview: CTT Systems AB (publ) designs, manufactures, and sells humidity control systems for aircraft in Sweden, Denmark, France, the United States, and internationally with a market cap of SEK3.42 billion.
Operations: The company generates revenue primarily from its Aerospace & Defense segment, amounting to SEK317.70 million.
Insider Ownership: 16.9%
Earnings Growth Forecast: 24.8% p.a.
CTT Systems, with substantial insider ownership, is forecast to grow revenue by 21.9% annually, significantly outpacing the Swedish market's 1.1%. Earnings are expected to increase by 24.8% per year over the next three years. Recent corporate guidance projects a net sales increase of up to 16% for H2 2024 compared to last year. Insider activity has been positive with more shares bought than sold in the past three months, reinforcing confidence in its growth trajectory.
- Dive into the specifics of CTT Systems here with our thorough growth forecast report.
- Our expertly prepared valuation report CTT Systems implies its share price may be lower than expected.
Scandi Standard (OM:SCST)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Scandi Standard AB (publ) produces and sells chilled, frozen, and ready-to-eat chicken products across several European countries and internationally, with a market cap of SEK5.28 billion.
Operations: The company's revenue segments consist of SEK2.61 billion from Ready-To-Eat products and SEK9.70 billion from Ready-To-Cook products.
Insider Ownership: 14.6%
Earnings Growth Forecast: 20.4% p.a.
Scandi Standard, with significant insider ownership, is expected to grow earnings by 20.4% annually over the next three years, outpacing the Swedish market's 15.7%. Recent Q2 2024 results showed stable performance with net income at SEK 71 million. The company secured a SEK 3,200 million sustainability-linked bank loan aimed at refinancing and supporting growth initiatives. Insider activity has been positive recently, indicating confidence in its future prospects despite a high debt level and an unstable dividend track record.
- Take a closer look at Scandi Standard's potential here in our earnings growth report.
- In light of our recent valuation report, it seems possible that Scandi Standard is trading behind its estimated value.
Taking Advantage
- Investigate our full lineup of 89 Fast Growing Swedish Companies With High Insider Ownership right here.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Want To Explore Some Alternatives?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if BioArctic might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About OM:BIOA B
BioArctic
Develops biological drugs for patients with disorders of the central nervous system in Sweden.